Natural Product (NP) Details

General Information of the NP (ID: NP0871)
Name
Isotretinoin
Synonyms
Isotretinoin; 13-cis-Retinoic acid; 4759-48-2; Accutane; Roaccutane; Neovitamin A acid; 13-cis-Vitamin A acid; 13-cis retinoic acid; Claravis; Amnesteem; Isotrex; Teriosal; Sotret; ISOTRETINON; isotretinoino; Isotretinoine; Isotretinoinum; Roaccutan; 13-RA; Absorica; Roacutan; Isotretinoine [INN-French]; Isotretinoinum [INN-Latin]; Isotretinoino [INN-Spanish]; CIP-Isotretinoin; Accutane (TN); Isotretinoin (USP); Ro-4-3780; UNII-EH28UP18IF; cis-RA; (7E,9E,11E,13Z)-retinoic acid; Ro 4-3780; (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid; (13cis)-retinoic acid; 13-cis RA; Ro-43780; CHEMBL547; EH28UP18IF; RETINOIC ACID, 13-cis-; CHEBI:6067; 13-cis-retinoic acid,Isotretinoin; Isotane; (2Z,4E6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid; cis-Retinoic acid; Myorisan; Zenatane; Isosuprea Lidose; Sotret (TN); CCRIS 4286; HSDB 3929; 13 Cis-Retinoic Acid; SR-01000076103; EINECS 225-296-0; BRN 1885770; isotretinoina; cis-Retinoate; BML2-E07; Isotretinoin [USAN:BAN:INN]; MFCD00079542; cis retinoic acid; Trans-Retinoicacid; Absorica (TN); Prestwick_642; CAS-4759-48-2; Isotretinoin [USAN:USP:INN:BAN]; (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic acid; (13-cis)-Retinoate; CPD000471891; 13cRA; Prestwick2_000256; Prestwick3_000256; Spectrum5_001795; Spectrum5_001937; (13-cis)-Retinoic acid; DSSTox_CID_3177; R 3255; Retinoic acid 13-cis-form; Retinoic acid, (13cis)-; DSSTox_RID_76906; DSSTox_GSID_23177; Lopac0_001081; SCHEMBL38299; BSPBio_000072; BSPBio_001331; BSPBio_003345; 4-09-00-02388 (Beilstein Handbook Reference); MLS001074662; SPECTRUM1502013; BPBio1_000080; GTPL7600; DTXSID4023177; PAT-001; HMS1361C13; HMS1568D14; HMS1791C13; HMS1921D08; HMS1989C13; HMS2092N07; HMS2095D14; HMS2233A07; HMS3259J09; HMS3263I04; HMS3402C13; HMS3712D14; HMS3884A13; Pharmakon1600-01502013; BCP18950; ZINC3792789; Tox21_200093; Tox21_501081; BDBM50031459; LMPR01090021; NSC758156; 13-Cis- Retionic acid(Isotretinoin); AKOS015841158; CCG-205158; CS-1864; DB00982; DS-3367; LP01081; NC00635; NSC 758156; NSC-758156; SDCCGSBI-0051051.P004; IDI1_033801; NCGC00094358-01; NCGC00094358-02; NCGC00094358-03; NCGC00094358-04; NCGC00094358-05; NCGC00094358-06; NCGC00094358-07; NCGC00094358-08; NCGC00094358-09; NCGC00094358-10; NCGC00094358-11; NCGC00094358-12; NCGC00094358-13; NCGC00094358-14; NCGC00094358-15; NCGC00094358-26; NCGC00257647-01; NCGC00261766-01; HY-15127; SMR000471891; 13-cis-Retinoic acid, >=98% (HPLC); 13-cis-Retinoic acid; ; ; Retinoid analogues; SBI-0051051.P003; EU-0101081; R0088; 5952-EP0930075A1; 5952-EP2295426A1; 5952-EP2311840A1; 59I482; C07058; D00348; 24210-EP2311808A1; 24210-EP2311829A1; 24210-EP2314590A1; Q287029; SR-01000076103-2; SR-01000076103-5; SR-01000076103-6; SR-01000076103-9; BRD-K76723084-001-05-9; SR-01000076103-10; Isotretinoin, European Pharmacopoeia (EP) Reference Standard; Isotretinoin, United States Pharmacopeia (USP) Reference Standard; (2Z,4E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraenoic acid; Isotretinoin for peak identification, European Pharmacopoeia (EP) Reference Standard; Isotretinoin, Pharmaceutical Secondary Standard; Certified Reference Material; (2Z,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid; (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid
    Click to Show/Hide
Species Origin Homo sapiens ...     Click to Show/Hide
Homo sapiens
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Disease Acne vulgaris [ICD-11: ED80] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C20H28O2
PubChem CID
5282379
Canonical SMILES
CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C
InChI
1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14-
InChIKey
SHGAZHPCJJPHSC-XFYACQKRSA-N
CAS Number
CAS 4759-48-2
ChEBI ID
CHEBI:6067
TTD Drug ID
D00DKK
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Desloratadine      Vasomotor/allergic rhinitis     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Clinical Trial
                    Experimental
                    Result(s)		 While no side effects other than dryness of the lips were noted, a significant reduction of the erythema and edema could be observed in all patients.
Target and Pathway
Target(s) Retinoic acid receptor (RAR)  Molecule Info  [3]
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7600).
Reference 2 Combination of ultra-low-dose isotretinoin and antihistamines in treating Morbihan disease - a new long-term approach with excellent results and a minimum of side effects. J Dermatolog Treat. 2020 Feb 5;1-4.
Reference 3 Retinoid agonist isotretinoin ameliorates obstructive renal injury. J Urol. 2003 Oct;170(4 Pt 1):1398-402.
 Download Picture         KEGG Link